For beta-lactams, including penicillin, non-penicillin beta-lactam antibacterials, as well as non-antibacterial beta-lactam drugs, APIs, and intermediates, regulatory expectations are complete and comprehensive physical separation of manufacturing, packaging, and other operations. Regulatory guidance’s mandate a robust contamination control strategy involving:

·       Separate air handling units (AHUs)

·       Dedicated equipment

·       Controlled waste flow

·       Management of exhaust systems

·       Separation of utilities and vacuum systems

·       Defined flows for personnel, materials, and gowning

·       Separate entry and exit points

·       Effective decontamination procedures

These measures are essential due to the highly sensitizing nature of beta-lactams, the difficulty in determining sensitization potential. Extrapolating from this, documents from beta-lactam manufacturing and operational areas should have a dedicated document archival and documentation cell, not shared with general products documentation archival.

For other molecules such as cytotoxic or high-potency drugs, dedicated document archival systems are recommended, especially for products categorized under OEB (Occupational Exposure Band) 4 or OEB 5. Alternate strategies may be considered, provided they are supported by robust data. Such strategies include:

•      Decontamination protocols

•      Use of air showers at operational exits

•      Protective covers and containers for documents

•      Procedural controls for document handling in designated areas

And it should be demonstrated that contamination risks are maintained well below defined acceptable levels - well-defined PDE (Permitted Daily Exposure) as per the European Medicines Agency (EMA) guidelines on setting health-based exposure limits.

Reference:

•      USFDA Guidenance: Non-Penicillin BetaLactam Drugs: A CGMP Framework for Preventing Cross-Contamination